INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7001, 26610, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7002, 26614, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7003, 26615, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7004, 26616, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7005, 26617, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7006, 26618, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7007, 26619, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7008, 31991, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7009, 32347, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7010, 32440, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7011, 32441, 'Aripiprazole', 'Parkinsonian Disorders', 'The use of neuroleptic agents is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Older neuroleptic agents such as haloperidol are more likely to induce these effects, and their use may be contraindicated in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'Moleman P, Janzen G, von Bargen BA, et al. "Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol." Am J Psychiatry 143 (1986):  232-4|"Product Information. Haldol (haloperidol)." McNeil Pharmaceutical  (2002):|Heel RC, Brogden RN, Speight TM, Avery GS "Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent." Drugs 15 (1978):  198-217|Bransgrove LL, Kelly MW "Movement disorders in patients treated with long-acting injectable antipsychotic drugs." Am J Hosp Pharm 51 (1994):  895-9|Owens DGC "Extrapyramidal side effects and tolerability of risperidone - a review." J Clin Psychiatry 55 Suppl (1994):  29-35|Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS "Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry." Drugs 12 (1976):  1-40|Sheppard C, Merlis S "Drug-induced extrapyramidal symptoms: their incidence and treatment." Am J Psychiatry 123 (1967):  886-9|Boston Collaborative Drug Surveillance Program "Drug-induced extrapyramidal symptoms." JAMA 224 (1973):  889-91|Mahmood T, Clothier EB, Bridgman R "Risperidone-induced extrapyramidal reactions." Lancet 346 (1995):  1226|Gwinn KA, Caviness JN "Risperidone-induced tardive dyskinesia and parkinsonism." Mov Disord 12 (1997):  119-21|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|"Product Information. Loxitane C (loxapine)." Apothecon Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7012, 17, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7013, 18, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7014, 20, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7015, 21, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7016, 22, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7017, 204, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7018, 205, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7019, 925, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7020, 927, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7021, 940, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7022, 943, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7023, 946, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7024, 948, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7025, 950, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7026, 952, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7027, 1766, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7028, 3339, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7029, 10222, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7030, 14308, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7031, 14309, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7032, 14310, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7033, 14311, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7034, 14392, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7035, 14393, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7036, 14394, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7037, 14400, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7038, 14401, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7039, 14404, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7040, 25140, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7041, 26610, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7042, 26614, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7043, 26615, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7044, 26616, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7045, 26617, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7046, 26618, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7047, 26619, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7048, 31991, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7049, 32347, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7050, 32440, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7051, 32441, 'Aripiprazole', 'Tardive Dyskinesia', 'Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs; the syndrome consists of potentially irreversible, involuntary, dyskinetic movements.  The risk appears highest in older patients (particularly older women) but it is not possible to predict which patients are likely to develop TD; whether antipsychotic drugs differ in their potential to cause TD is unknown.  The risk of TD and the likelihood that it will become irreversible increase with the duration of therapy and the total cumulative dose.  The syndrome can develop after relatively brief treatment periods, even at low dosages; it may also occur after discontinuation of therapy.  TD may remit (partially or completely) upon discontinuation of antipsychotic therapy, although antipsychotic therapy itself may suppress (or partially suppress) signs/symptoms of TD, possibly masking the underlying process; the effect of symptomatic suppression on the long-term course of TD is unknown.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of antipsychotic therapy may temporarily mask the symptoms of TD but could eventually worsen the condition.  In patients requiring chronic therapy, the lowest dose and shortest duration of therapy producing a satisfactory clinical response are recommended; the need for continued therapy should be reassessed periodically.  If signs/symptoms of TD occur during antipsychotic therapy, discontinuation of the offending agent should be considered; however, some patients may require treatment despite the presence of TD.', '2', '"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):|"Product Information. Haldol (haloperidol)." Janssen Pharmaceuticals  (2020):|"Product Information. Thiothixene (thiothixene)." Amneal Pharmaceuticals LLC  (2022):|"Product Information. Clozaril (cloZAPine)." HLS Therapeutics Inc  (2021):|"Product Information. RisperDAL (risperiDONE)." Janssen Pharmaceuticals  (2021):|"Product Information. ZyPREXA (OLANZapine)." Lilly, Eli and Company  (2020):|"Product Information. Moban (molindone)." Endo Laboratories LLC  (2017):|"Product Information. Pimozide (pimozide)." Par Pharmaceutical Inc  (2017):|"Product Information. Geodon (ziprasidone)." Pfizer Inc.  (2022):|"Product Information. Loxapine Succinate (loxapine)." Actavis U.S. (Amide Pharmaceutical Inc)  (2016):|"Product Information. Invega (paliperidone)." Janssen Pharmaceuticals  (2022):|"Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc  (2017):|"Product Information. Saphris (asenapine)." Schering-Plough Corporation  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7052, 14411, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7053, 14412, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7054, 14413, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7055, 14414, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7056, 14415, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7057, 14416, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7058, 29614, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7059, 29615, 'Armodafinil', 'Alcoholism', 'Patients with excessive sleepiness, including those taking armodafinil, should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.  Patients should refrain from drinking alcohol while taking armodafinil as any drug affecting the central nervous system (CNS) may alter judgment, thinking or motor skills.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7060, 14411, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7061, 14412, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7062, 14413, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7063, 14414, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7064, 14415, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7065, 14416, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7066, 29614, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7067, 29615, 'Armodafinil', 'Cardiomyopathies', 'Armodafinil may cause ECG changes, chest pain, or arrhythmia.  Armodafinil should be used with caution in patients with cardiovascular complications.  Armodafinil should not be used in patients with a history of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants.  It is recommended to monitor heart rate and blood pressure during treatment with armodafinil.  Caution should be exercised when prescribing armodafinil to patients with known cardiovascular disease.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7068, 14411, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7069, 14412, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7070, 14413, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7071, 14414, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7072, 14415, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7073, 14416, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7074, 29614, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7075, 29615, 'Armodafinil', 'Liver Diseases', 'In a study to determine the pharmacokinetics and metabolism of armodafinil in patients with cirrhosis, the oral clearance of armodafinil was decreased by about 60%, and the steady state concentration was doubled compared to healthy patients.  The dosage of armodafinil should be reduced in patients with severe hepatic impairment.  Close monitoring is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7076, 14411, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7077, 14412, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7078, 14413, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7079, 14414, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7080, 14415, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7081, 14416, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7082, 29614, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7083, 29615, 'Armodafinil', 'Mental Disorders', 'Armodafinil may cause adverse psychiatric reactions.  Caution should be exercised when using this agent in patients with a history of psychosis, depression, or mania.  If psychiatric symptoms develop in association with armodafinil administration, consider discontinuing armodafinil.  Close monitoring of psychiatric symptoms is recommended.', '2', '"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7084, 14411, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7085, 14412, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7086, 14413, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7087, 14414, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7088, 14415, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7089, 14416, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7090, 29614, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7091, 29615, 'Armodafinil', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7092, 14411, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7093, 14412, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7094, 14413, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7095, 14414, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7096, 14415, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7097, 14416, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7098, 29614, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7099, 29615, 'Armodafinil', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7100, 974, 'Methylcellulose', 'Intestinal Obstruction', 'The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction.  Bulk producing laxatives can exacerbate these conditions.', '3', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7101, 9303, 'Methylcellulose', 'Intestinal Obstruction', 'The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction.  Bulk producing laxatives can exacerbate these conditions.', '3', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7102, 11222, 'Methylcellulose', 'Intestinal Obstruction', 'The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction.  Bulk producing laxatives can exacerbate these conditions.', '3', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7103, 21637, 'Methylcellulose', 'Intestinal Obstruction', 'The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction.  Bulk producing laxatives can exacerbate these conditions.', '3', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7104, 22092, 'Methylcellulose', 'Intestinal Obstruction', 'The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction.  Bulk producing laxatives can exacerbate these conditions.', '3', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7105, 27954, 'Methylcellulose', 'Intestinal Obstruction', 'The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction.  Bulk producing laxatives can exacerbate these conditions.', '3', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):|"Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7106, 974, 'Methylcellulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7107, 9303, 'Methylcellulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7108, 11222, 'Methylcellulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7109, 21637, 'Methylcellulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7110, 22092, 'Methylcellulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7111, 27954, 'Methylcellulose', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '"Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc  (2001):|"Product Information. Fleet Bisacodyl (bisacodyl)." Fleet|"Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb|"Product Information. Neoloid (castor oil)." Paddock Laboratories Inc  (2001):|"Product Information. SenoSol-X (senna)." Apothecon Inc  (2022):|"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7112, 974, 'Methylcellulose', 'Kidney Diseases', 'Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose.  Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.', '2', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7113, 9303, 'Methylcellulose', 'Kidney Diseases', 'Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose.  Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.', '2', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7114, 11222, 'Methylcellulose', 'Kidney Diseases', 'Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose.  Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.', '2', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7115, 21637, 'Methylcellulose', 'Kidney Diseases', 'Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose.  Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.', '2', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7116, 22092, 'Methylcellulose', 'Kidney Diseases', 'Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose.  Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.', '2', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7117, 27954, 'Methylcellulose', 'Kidney Diseases', 'Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose.  Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.', '2', '"Product Information. FiberCon (polycarbophil)." Lederle Laboratories  (2001):|"Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7118, 0, 'Methscopolamine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7119, 0, 'Methscopolamine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', 'Bantz EW, Dolen WK, Chadwick EW, Nelson HS "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy 59 (1987):  341-6|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Blamoutier J "Comparative trial of two antihistamines, mequitazine and brompheniramine." Curr Med Res Opin 5 (1978):  366-70|"Azatadine (optimine)--a new antihistamine." Med Lett Drugs Ther 19 (1977):  77-9|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Mevorach D "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother 26 (1992):  564|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7120, 0, 'Methscopolamine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|O''Connor PS, Mumma JV "Atropine toxicity." Am J Ophthalmol 99 (1985):  613-4|Clearkin LG "Angle closure glaucoma precipitated by atropine." Arch Intern Med 152 (1992):  880|Berdy GJ, Berdy SS, Odin LS, Hirst LW "Angle closure glaucoma precipitated by aerosolized atropine." Arch Intern Med 151 (1991):  1658-60|Pecora JL "Malignant glaucoma worsened by miotics in a postoperative angle- closure glaucoma patient." Ann Ophthalmol 11 (1979):  1412-4|Holland MG "Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs." Ann Ophthalmol 6 (1974):  661-4|Kanto J "New aspects in the use of atropine." Int J Clin Pharmacol Ther Toxicol 21 (1983):  92-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971):  13-34|"Product Information. Cogentin (benztropine)." Merck & Co., Inc  (2001):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7121, 0, 'Methscopolamine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', 'Bantz EW, Dolen WK, Chadwick EW, Nelson HS "Chronic chlorpheniramine therapy: subsensitivity, drug metabolism, and compliance." Ann Allergy 59 (1987):  341-6|Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Thorazine (chlorpromazine)." SmithKline Beecham  (2002):|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Shutt LE, Bowes JB "Atropine and hyoscine." Anaesthesia 34 (1979):  476-90|O''Kelly SW, Spargo PM "Postoperative urinary retention in men." BMJ 302 (1991):  1403-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Compazine (prochlorperazine)." SmithKline Beecham  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Moban (molindone)." Gate Pharmaceuticals  (2001):|"Product Information. Orap (pimozide)." Gate Pharmaceuticals|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7122, 0, 'Methscopolamine', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', 'Nahata MC, Clotz MA, Krogg EA "Adverse effects of meperidine, promethazine, and chlorpromazine for sedation in pediatric patients." Clin Pediatr (Phila) 24 (1985):  558-60|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7123, 0, 'Methscopolamine', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', 'Shutt LE, Bowes JB "Atropine and hyoscine." Anaesthesia 34 (1979):  476-90|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7124, 0, 'Methscopolamine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', 'Brown JW "Toxic megacolon associated with loperamide therapy." JAMA 241 (1979):  501-2|Walley T, Milson D "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J 66 (1990):  582|"Product Information. Imodium (loperamide)." Janssen Pharmaceuticals  (2001):|Marshall WF Jr, Rosenthal P, Merritt RJ "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr 9 (1989):  532-4|"Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975):  104|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7125, 0, 'Methscopolamine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|Lowenthal DT, Reidenberg MM "The heart rate response to atropine in uremic patients, obese subjects before and during fasting, and patients with other chronic illnesses." Proc Soc Exp Biol Med 139 (1972):  390-3|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|Lunde P "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand 199 (1976):  369-71|Cooper MJ, Abinader EG "Atropine-induced ventricular fibrillation: case report and review of the literature." Am Heart J 97 (1979):  225-8|Das G, Talmers FN, Weissler AM "New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man." Am J Cardiol 36 (1975):  281-5|Knoebel SB, McHenry PL, Phillips JF, Widlansky S "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol 33 (1974):  327-32|Bradshaw EG "Dysrhythmias associated with oral surgery." Anaesthesia 31 (1976):  13-7|Horgan J "Atropine and ventricular tachyarrhythmia." JAMA 223 (1973):  693|Zsigmond EK, Matsuki A, Sharafabadi C "Atropine and cardiac arrhythmia." N Engl J Med 288 (1973):  635|Massumi RA, Mason DT, Amsterdam EA, DeMaria A, Miller RR, Scheinman MM, Zelis R "Ventricular fibrillation and tachycardia after intravenous atropine for treatment of bradycardias." N Engl J Med 287 (1972):  336-8|Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984):  621-4|Lazzari JO, Benchuga EG, Elizari MV, Rosenbaum MB "Ventricular fibrillation after intravenous atropine in a patient with atrioventricular block." Pacing Clin Electrophysiol 5 (1982):  196-200|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7126, 0, 'Methscopolamine', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', '"Product Information. Antivert (meclizine)." Roerig Division  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7127, 0, 'Methscopolamine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', 'Lunde P "Ventricular fibrillation after intravenous atropine for treatment of sinus bradycardia." Acta Med Scand 199 (1976):  369-71|Knoebel SB, McHenry PL, Phillips JF, Widlansky S "Atropine-induced cardioacceleration and myocardial blood flow in subjects with and without coronary artery disease." Am J Cardiol 33 (1974):  327-32|Richman S "Adverse effect of atropine during myocardial infarction. Enchancement of ischemia following intravenously administered atropine." JAMA 228 (1974):  1414-6|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7128, 0, 'Methscopolamine', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', 'Chernish SM, Brunelle RR, Rosenak BD, Ahmadzai S "Comparison of the effects of glucagon and atropine sulfate on gastric emptying." Am J Gastroenterol 70 (1978):  581-6|Mevorach D "Adverse effects of atropine sulfate autoinjection." Ann Pharmacother 26 (1992):  564|Cotton BR, Smith G "Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure." Br J Anaesth 53 (1981):  869-74|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7129, 0, 'Methscopolamine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', 'Chernish SM, Brunelle RR, Rosenak BD, Ahmadzai S "Comparison of the effects of glucagon and atropine sulfate on gastric emptying." Am J Gastroenterol 70 (1978):  581-6|Dow TG, Brock-Utne JG, Rubin J, Welman S, Dimopoulos GE, Moshal MG "The effect of atropine on the lower esophageal sphincter in late pregnancy." Obstet Gynecol 51 (1978):  426-30|Howells TH "The administration of metoclopramide with atropine." Anaesthesia 32 (1977):  677|Brock-Utne JG, Rubin J, Downing JW, Dimopoulos GE, Moshal MG, Naicker M "The administration of metoclopramide with atropine. A drug interaction effect on the gastro-oesophageal sphincter in man." Anaesthesia 31 (1976):  1186-90|Cotton BR, Smith G "Single and combined effects of atropine and metoclopramide on the lower oesophageal sphincter pressure." Br J Anaesth 53 (1981):  869-74|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7130, 0, 'Methscopolamine', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', 'Famewo CE "A re-evaluation of anticholergic premedication." Can Anaesth Soc J 24 (1977):  39-41|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Bentyl (dicyclomine)." Aventis Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7131, 0, 'Methscopolamine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|Valentin N, Staffeldt H, Kyst A "Effect of i.v. atropine on cardiac rhythm, heart rate, blood pressure and airway secretion during isoflurane anaesthesia." Acta Anaesthesiol Scand 28 (1984):  621-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Artane (trihexyphenidyl)." Lederle Laboratories  (2001):|"Product Information. Atropisol (atropine ophthalmic)." Ciba Vision Ophthalmics  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7132, 0, 'Methscopolamine', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7133, 0, 'Methscopolamine', 'Diarrhea', 'Diarrhea may be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy.  Antimuscarinic agents may further aggravate the diarrhea.  Therefore, these drugs should be administered cautiously in patients with diarrhea.', '1', '"Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975):  104|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7134, 0, 'Methscopolamine', 'Fever', 'Atropine-like agents may increase the risk of hyperthermia in patients with fever by producing anhidrosis.  Therapy with atropine-like agents should be administered cautiously in febrile patients.', '1', 'Stadnyk AN, Glezos JD "Drug-induced heat stroke." Can Med Assoc J 128 (1983):  957-9|Sarnquist F, Larson CP Jr "Drug-induced heat stroke." Anesthesiology 39 (1973):  348-50|Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986):  571|Forester D "Fatal drug-induced heat stroke." JACEP 7 (1978):  243-4|"Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics  (2022):|"Product Information. Cogentin (benztropine)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7135, 0, 'Methsuximide', 'Hematologic Diseases', 'Hematologic toxicities, some with fatal outcome, have been associated with the use of succinimide anticonvulsants.  Leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, and eosinophilia have been reported.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow suppression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and periodically during therapy.  Marked depression of blood counts may be indication for withdrawal of succinimide therapy.', '3', 'American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Seip M "Aplastic anemia during ethosuximide medication. Treatment with bolus- methylprednisolone." Acta Paediatr Scand 72 (1983):  927-9|Massey GV, Dunn NL, Heckel JL, Myer EC, Russell EC "Aplastic anemia following therapy for absence seizures with ethosuximide." Pediatr Neurol 11 (1994):  59-61|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7136, 0, 'Methsuximide', 'Liver Diseases', 'Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals.  In humans, abnormalities in liver and renal function studies have been reported.  Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases.  Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.', '3', 'Silverman SH, Gribetz D, Rausen AR "Nephrotic syndrome associated with ethosuccimide." Am J Dis Child 132 (1978):  99|Coulter DL "Ethosuximide-induced liver dysfunction." Arch Neurol 40 (1983):  393-4|Korinthenberg R, Wehrle L, Zimmerhackl LB "Renal tubular dysfunction following treatment with anti-epileptic drugs." Eur J Pediatr 153 (1994):  855-8|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7137, 0, 'Methsuximide', 'Lupus Erythematosus, Systemic', 'Cases of systemic lupus erythematosus (SLE) have been reported in association with the use of succinimide anticonvulsants, primarily ethosuximide.  Some of the patients recovered promptly following discontinuation of the drug, while others continued to have active disease long after.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with a history of SLE.', '3', 'Teoh PC, Chan HL "Lupus-scleroderma syndrome induced by ethosuximide." Arch Dis Child 50 (1975):  658-61|Beernink DH, Miller JJ 3d "Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children." J Pediatr 82 (1973):  113-7|Alter BP "Systemic lupus erythematosus and ethosuccimide." J Pediatr 77 (1970):  1093-5|Dabbous IA, Idriss HM "Occurrence of systemic lupus erythematosus in association with ethosuccimide therapy. Case report." J Pediatr 76 (1970):  617-20|Livingston S, Rodriguez H, Greene CA, Pauli LL "Systemic lupus erythematosus. Occurrence in association with ethosuximide therapy." JAMA 203 (1968):  731-2|Singsen BH, Fishman L, Hanson V "Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants." Pediatrics 57 (1976):  529-34|"Product Information. Zarontin (ethosuximide)." Parke-Davis  (2001):|"Product Information. Milontin (phensuximide)." Parke-Davis  (2001):|"Product Information. Celontin (methsuximide)." Parke-Davis', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7138, 0, 'Methsuximide', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7139, 2971, 'Methylphenidate', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7140, 2972, 'Methylphenidate', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7141, 12975, 'Methylphenidate', 'Mental Disorders', 'The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated.  CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children.  Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7142, 2971, 'Methylphenidate', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7143, 2972, 'Methylphenidate', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7144, 12975, 'Methylphenidate', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7145, 2971, 'Methylphenidate', 'Glaucoma', 'The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7146, 2972, 'Methylphenidate', 'Glaucoma', 'The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7147, 12975, 'Methylphenidate', 'Glaucoma', 'The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7148, 2971, 'Methylphenidate', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7149, 2972, 'Methylphenidate', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7150, 12975, 'Methylphenidate', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7151, 2971, 'Methylphenidate', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7152, 2972, 'Methylphenidate', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7153, 12975, 'Methylphenidate', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7154, 2971, 'Methylphenidate', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7155, 2972, 'Methylphenidate', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7156, 12975, 'Methylphenidate', 'Substance-Related Disorders', 'Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse.  Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use.  Frank psychotic episodes may also occur in association with chronic intoxication.  Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse.  The use of amphetamines is considered by manufacturers to be contraindicated in such patients.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7157, 2971, 'Methylphenidate', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7158, 2972, 'Methylphenidate', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7159, 12975, 'Methylphenidate', 'Tics', 'Central nervous system (CNS) stimulants have been reported to exacerbate Tourette''s syndrome and other motor and phonic tics.  Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette''s syndrome.  The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7160, 2971, 'Methylphenidate', 'Epilepsy', 'There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures.  The medication should be discontinued if seizures occur during its use.', '3', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7161, 2972, 'Methylphenidate', 'Epilepsy', 'There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures.  The medication should be discontinued if seizures occur during its use.', '3', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7162, 12975, 'Methylphenidate', 'Epilepsy', 'There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures.  The medication should be discontinued if seizures occur during its use.', '3', NULL, 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7163, 2971, 'Methylphenidate', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7164, 2972, 'Methylphenidate', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7165, 12975, 'Methylphenidate', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7166, 2971, 'Methylphenidate', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7167, 2972, 'Methylphenidate', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7168, 12975, 'Methylphenidate', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7169, 2971, 'Methylphenidate', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7170, 2972, 'Methylphenidate', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7171, 12975, 'Methylphenidate', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7172, 2971, 'Methylphenidate', 'Hematologic Diseases', 'Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate.  However, a causal relationship has not been established.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.', '2', '"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7173, 2972, 'Methylphenidate', 'Hematologic Diseases', 'Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate.  However, a causal relationship has not been established.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.', '2', '"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7174, 12975, 'Methylphenidate', 'Hematologic Diseases', 'Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate.  However, a causal relationship has not been established.  Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.', '2', '"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7175, 2971, 'Methylphenidate', 'Intestinal Obstruction', 'The extended-release formulation of methylphenidate (Concerta) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  The extended-release formulation of methylphenidate should ordinarily not be administered in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic (e.g., small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel''s diverticulum).  The medication should only be used in patients who are able to swallow the tablet whole.', '2', '"Product Information. Concerta (methylphenidate)." Alza  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7176, 2972, 'Methylphenidate', 'Intestinal Obstruction', 'The extended-release formulation of methylphenidate (Concerta) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  The extended-release formulation of methylphenidate should ordinarily not be administered in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic (e.g., small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel''s diverticulum).  The medication should only be used in patients who are able to swallow the tablet whole.', '2', '"Product Information. Concerta (methylphenidate)." Alza  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7177, 12975, 'Methylphenidate', 'Intestinal Obstruction', 'The extended-release formulation of methylphenidate (Concerta) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  The extended-release formulation of methylphenidate should ordinarily not be administered in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic (e.g., small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel''s diverticulum).  The medication should only be used in patients who are able to swallow the tablet whole.', '2', '"Product Information. Concerta (methylphenidate)." Alza  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7178, 3423, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7179, 12369, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7180, 18476, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7181, 22157, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7182, 22660, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7183, 22661, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7184, 26026, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7185, 28809, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7186, 29754, 'Methylprednisolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7187, 3423, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7188, 12369, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7189, 18476, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7190, 22157, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7191, 22660, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7192, 22661, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7193, 26026, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7194, 28809, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7195, 29754, 'Methylprednisolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7196, 3423, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7197, 12369, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7198, 18476, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7199, 22157, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7200, 22660, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7201, 22661, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7202, 26026, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7203, 28809, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7204, 29754, 'Methylprednisolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7205, 3423, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7206, 12369, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7207, 18476, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7208, 22157, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7209, 22660, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7210, 22661, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7211, 26026, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7212, 28809, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7213, 29754, 'Methylprednisolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7214, 3423, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7215, 12369, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7216, 18476, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7217, 22157, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7218, 22660, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7219, 22661, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7220, 26026, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7221, 28809, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7222, 29754, 'Methylprednisolone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7223, 3423, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7224, 12369, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7225, 18476, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7226, 22157, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7227, 22660, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7228, 22661, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7229, 26026, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7230, 28809, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7231, 29754, 'Methylprednisolone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7232, 3423, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7233, 12369, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7234, 18476, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7235, 22157, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7236, 22660, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7237, 22661, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7238, 26026, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7239, 28809, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7240, 29754, 'Methylprednisolone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7241, 3423, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7242, 12369, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7243, 18476, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7244, 22157, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7245, 22660, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7246, 22661, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7247, 26026, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7248, 28809, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7249, 29754, 'Methylprednisolone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7250, 3423, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7251, 12369, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7252, 18476, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7253, 22157, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7254, 22660, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7255, 22661, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7256, 26026, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7257, 28809, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7258, 29754, 'Methylprednisolone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7259, 3423, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7260, 12369, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7261, 18476, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7262, 22157, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7263, 22660, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7264, 22661, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7265, 26026, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7266, 28809, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7267, 29754, 'Methylprednisolone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986):  139-42|"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7268, 3423, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7269, 12369, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7270, 18476, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7271, 22157, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7272, 22660, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7273, 22661, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7274, 26026, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7275, 28809, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7276, 29754, 'Methylprednisolone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7277, 3423, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7278, 12369, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7279, 18476, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7280, 22157, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7281, 22660, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7282, 22661, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7283, 26026, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7284, 28809, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7285, 29754, 'Methylprednisolone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|Cunliffe WJ, Burton JL, Holti G, Wright V "Hazards of steroid therapy in hepatic failure." Br J Dermatol 93 (1975):  183-5|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7286, 3423, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7287, 12369, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7288, 18476, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7289, 22157, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7290, 22660, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7291, 22661, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7292, 26026, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7293, 28809, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7294, 29754, 'Methylprednisolone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7295, 3423, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7296, 12369, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7297, 18476, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7298, 22157, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7299, 22660, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7300, 22661, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7301, 26026, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7302, 28809, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7303, 29754, 'Methylprednisolone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7304, 3423, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7305, 12369, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7306, 18476, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7307, 22157, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7308, 22660, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7309, 22661, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7310, 26026, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7311, 28809, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7312, 29754, 'Methylprednisolone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7313, 3423, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7314, 12369, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7315, 18476, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7316, 22157, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7317, 22660, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7318, 22661, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7319, 26026, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7320, 28809, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7321, 29754, 'Methylprednisolone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7322, 3423, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7323, 12369, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7324, 18476, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7325, 22157, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7326, 22660, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7327, 22661, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7328, 26026, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7329, 28809, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7330, 29754, 'Methylprednisolone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7331, 3423, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7332, 12369, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7333, 18476, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7334, 22157, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7335, 22660, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7336, 22661, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7337, 26026, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7338, 28809, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7339, 29754, 'Methylprednisolone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7340, 3423, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7341, 12369, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7342, 18476, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7343, 22157, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7344, 22660, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7345, 22661, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7346, 26026, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7347, 28809, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7348, 29754, 'Methylprednisolone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7349, 3423, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7350, 12369, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7351, 18476, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7352, 22157, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7353, 22660, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7354, 22661, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7355, 26026, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7356, 28809, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7357, 29754, 'Methylprednisolone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7358, 3423, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7359, 12369, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7360, 18476, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7361, 22157, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7362, 22660, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7363, 22661, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7364, 26026, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7365, 28809, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7366, 29754, 'Methylprednisolone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7367, 3423, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7368, 12369, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7369, 18476, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7370, 22157, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7371, 22660, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7372, 22661, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7373, 26026, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7374, 28809, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7375, 29754, 'Methylprednisolone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', '"Product Information. Hydeltrasol (prednisolone)." Merck & Co., Inc  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Decadron (dexamethasone)." Merck & Co., Inc  (2001):|"Product Information. Hydrocortone (hydrocortisone)." Merck & Co., Inc  (2001):|"Product Information. Medrol (methylprednisolone)." Pharmacia and Upjohn  (2001):|"Product Information. Florinef Acetate (fludrocortisone)." Bristol-Myers Squibb  (2001):|"Product Information. Cortone Acetate (cortisone)." Merck & Co., Inc  (2001):|"Product Information. Kenalog (triamcinolone)." Bristol-Myers Squibb  (2001):|"Product Information. Celestone (betamethasone)." Schering Corporation  (2001):|"Product Information. Emflaza (deflazacort)." PTC Therapeutics, Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7376, 142, 'Methyldopa', 'Liver Diseases', 'The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders.  Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.', '3', 'Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973):  177-84|Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976):  1602-3|Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976):  2001-2|Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976):  941-8|Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976):  144-52|Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977):  429-35|Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977):  125-33|Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977):  579-81|Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982):  41-5|Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985):  1233-9|Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989):  57-60|Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978):  572-9|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7377, 272, 'Methyldopa', 'Liver Diseases', 'The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders.  Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.', '3', 'Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973):  177-84|Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976):  1602-3|Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976):  2001-2|Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976):  941-8|Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976):  144-52|Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977):  429-35|Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977):  125-33|Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977):  579-81|Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982):  41-5|Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985):  1233-9|Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989):  57-60|Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978):  572-9|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7378, 322, 'Methyldopa', 'Liver Diseases', 'The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders.  Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.', '3', 'Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973):  177-84|Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976):  1602-3|Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976):  2001-2|Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976):  941-8|Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976):  144-52|Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977):  429-35|Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977):  125-33|Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977):  579-81|Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982):  41-5|Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985):  1233-9|Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989):  57-60|Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978):  572-9|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7379, 4254, 'Methyldopa', 'Liver Diseases', 'The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders.  Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.', '3', 'Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973):  177-84|Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976):  1602-3|Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976):  2001-2|Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976):  941-8|Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976):  144-52|Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977):  429-35|Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977):  125-33|Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977):  579-81|Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982):  41-5|Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985):  1233-9|Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989):  57-60|Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978):  572-9|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7380, 8095, 'Methyldopa', 'Liver Diseases', 'The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders.  Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.', '3', 'Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973):  177-84|Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976):  1602-3|Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976):  2001-2|Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976):  941-8|Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976):  144-52|Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977):  429-35|Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977):  125-33|Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977):  579-81|Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982):  41-5|Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985):  1233-9|Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989):  57-60|Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978):  572-9|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7381, 21220, 'Methyldopa', 'Liver Diseases', 'The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders.  Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.', '3', 'Goldstein GB, Lam KC, Mistillis SP "Drug-induced active chronic hepatitis." Dig Dis 18 (1973):  177-84|Bonkowsky HL, Brisbane J "Colitis and hepatitis caused by methyldopa." JAMA 236 (1976):  1602-3|Miller AC, Reid WM "Methyldopa-induced granulomatous hepatitis." JAMA 235 (1976):  2001-2|Rodman JS, Deutsch DJ, Gutman SI "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med 60 (1976):  941-8|Cacace LG, Cohen M "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm 10 (1976):  144-52|Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol 12 (1977):  429-35|Thomas E, Rosenthal WS, Zapiach L, Micci D "Spectrum of methyldopa liver injury." Am J Gastroenterol 68 (1977):  125-33|Puppala AR, Steinheber FU "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol 68 (1977):  579-81|Bezahler GH "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci 283 (1982):  41-5|Neuberger J, Kenna JG, Aria KN, Williams R "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut 26 (1985):  1233-9|Moses A, Zahger D, Amir G "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion 42 (1989):  57-60|Lawson DH, Gloss D, Jick H "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J 96 (1978):  572-9|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7382, 142, 'Methyldopa', 'Cerebrovascular Disorders', 'Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease.  If these movements occur, therapy should be stopped.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7383, 272, 'Methyldopa', 'Cerebrovascular Disorders', 'Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease.  If these movements occur, therapy should be stopped.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7384, 322, 'Methyldopa', 'Cerebrovascular Disorders', 'Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease.  If these movements occur, therapy should be stopped.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7385, 4254, 'Methyldopa', 'Cerebrovascular Disorders', 'Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease.  If these movements occur, therapy should be stopped.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7386, 8095, 'Methyldopa', 'Cerebrovascular Disorders', 'Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease.  If these movements occur, therapy should be stopped.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7387, 21220, 'Methyldopa', 'Cerebrovascular Disorders', 'Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease.  If these movements occur, therapy should be stopped.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7388, 142, 'Methyldopa', 'Diseases requiring dialysis', 'Methyldopa is removed by dialysis.  Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.', '2', 'Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970):  840-3|Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972):  201-4|Myhre E, Stenbaek O, Rugstad HE, et al. "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982):  257-63|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7389, 272, 'Methyldopa', 'Diseases requiring dialysis', 'Methyldopa is removed by dialysis.  Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.', '2', 'Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970):  840-3|Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972):  201-4|Myhre E, Stenbaek O, Rugstad HE, et al. "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982):  257-63|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7390, 322, 'Methyldopa', 'Diseases requiring dialysis', 'Methyldopa is removed by dialysis.  Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.', '2', 'Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970):  840-3|Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972):  201-4|Myhre E, Stenbaek O, Rugstad HE, et al. "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982):  257-63|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7391, 4254, 'Methyldopa', 'Diseases requiring dialysis', 'Methyldopa is removed by dialysis.  Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.', '2', 'Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970):  840-3|Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972):  201-4|Myhre E, Stenbaek O, Rugstad HE, et al. "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982):  257-63|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7392, 8095, 'Methyldopa', 'Diseases requiring dialysis', 'Methyldopa is removed by dialysis.  Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.', '2', 'Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970):  840-3|Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972):  201-4|Myhre E, Stenbaek O, Rugstad HE, et al. "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982):  257-63|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7393, 21220, 'Methyldopa', 'Diseases requiring dialysis', 'Methyldopa is removed by dialysis.  Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.', '2', 'Yeh BK, Dayton PG, Waters WC III "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med 135 (1970):  840-3|Myhre E, Brodwall EK, Stenbaek O, Hansen T "The renal excretion of methyldopa." Scand J Clin Lab Invest 29 (1972):  201-4|Myhre E, Stenbaek O, Rugstad HE, et al. "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol 16 (1982):  257-63|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7394, 142, 'Methyldopa', 'Anemia, Hemolytic', 'Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs.  Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes.  Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended.  If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued', '2', 'Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970):  570-3|Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977):  1260-1|Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981):  54, 58|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7395, 272, 'Methyldopa', 'Anemia, Hemolytic', 'Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs.  Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes.  Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended.  If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued', '2', 'Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970):  570-3|Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977):  1260-1|Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981):  54, 58|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7396, 322, 'Methyldopa', 'Anemia, Hemolytic', 'Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs.  Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes.  Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended.  If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued', '2', 'Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970):  570-3|Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977):  1260-1|Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981):  54, 58|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7397, 4254, 'Methyldopa', 'Anemia, Hemolytic', 'Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs.  Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes.  Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended.  If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued', '2', 'Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970):  570-3|Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977):  1260-1|Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981):  54, 58|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7398, 8095, 'Methyldopa', 'Anemia, Hemolytic', 'Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs.  Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes.  Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended.  If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued', '2', 'Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970):  570-3|Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977):  1260-1|Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981):  54, 58|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7399, 21220, 'Methyldopa', 'Anemia, Hemolytic', 'Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs.  Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes.  Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended.  If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued', '2', 'Distenfeld A, Florita C, Gelfand ML "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med Feb (1970):  570-3|Nelson RB Jr, Nelson RB III "Methyldopa-associated intravascular hemolysis." Arch Intern Med 137 (1977):  1260-1|Roy A, Ghosh ML "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract 35 (1981):  54, 58|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7400, 142, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7401, 272, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7402, 322, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7403, 4254, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7404, 8095, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7405, 21220, 'Methyldopa', 'Leukopenia', 'Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted.  White blood cell counts returned to normal with discontinuation of methyldopa.  Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7406, 142, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', 'Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988):  700-1|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7407, 272, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', 'Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988):  700-1|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7408, 322, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', 'Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988):  700-1|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7409, 4254, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', 'Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988):  700-1|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7410, 8095, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', 'Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988):  700-1|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7411, 21220, 'Methyldopa', 'Edema', 'Methyldopa may cause edema or weight gain associated with sodium retention.  Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.', '2', 'Varkel Y, Braester A, Nusem D, Shkolnik T "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm 22 (1988):  700-1|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7412, 142, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', 'Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987):  168-70|Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988):  1555-8|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7413, 272, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', 'Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987):  168-70|Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988):  1555-8|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7414, 322, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', 'Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987):  168-70|Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988):  1555-8|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7415, 4254, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', 'Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987):  168-70|Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988):  1555-8|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7416, 8095, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', 'Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987):  168-70|Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988):  1555-8|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7417, 21220, 'Methyldopa', 'Pheochromocytoma', 'Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported.  This will interfere with the diagnosis of pheochromocytoma.  It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery.  Methyldopa is not recommended for the treatment of patients with pheochromocytoma.', '2', 'Cregler LL, Mark H "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med 54 (1987):  168-70|Rosen B, Ovsyshcher IA, Zimlichman R "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol 11 (1988):  1555-8|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7418, 142, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', 'Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978):  211-5|Wurzelmann J, Frishman WH, Aronson M, et al. "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987):  689-701|Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989):  1075-6|Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990):  128|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7419, 272, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', 'Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978):  211-5|Wurzelmann J, Frishman WH, Aronson M, et al. "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987):  689-701|Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989):  1075-6|Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990):  128|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7420, 322, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', 'Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978):  211-5|Wurzelmann J, Frishman WH, Aronson M, et al. "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987):  689-701|Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989):  1075-6|Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990):  128|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7421, 4254, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', 'Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978):  211-5|Wurzelmann J, Frishman WH, Aronson M, et al. "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987):  689-701|Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989):  1075-6|Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990):  128|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7422, 8095, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', 'Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978):  211-5|Wurzelmann J, Frishman WH, Aronson M, et al. "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987):  689-701|Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989):  1075-6|Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990):  128|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7423, 21220, 'Methyldopa', 'Psychotic Disorders', 'Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy.  Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.', '1', 'Endo M, Hirai KO, Ohara M "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology 3 (1978):  211-5|Wurzelmann J, Frishman WH, Aronson M, et al. "Neuropsychological effects of antihypertensive drugs." Cardiol Clin 5 (1987):  689-701|Labbate LA, Holzgang AJ "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry 146 (1989):  1075-6|Tchen P, Luchins DJ, Rose RP "Possibility of depression as a side effect of methyldopa." Am J Psychiatry 147 (1990):  128|"Product Information. Aldomet (methyldopa)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7424, 7196, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7425, 11072, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7426, 11073, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7427, 14146, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7428, 20022, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7429, 28077, 'Methyltestosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7430, 7196, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7431, 11072, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7432, 11073, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7433, 14146, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7434, 20022, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7435, 28077, 'Methyltestosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7436, 7196, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7437, 11072, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7438, 11073, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7439, 14146, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7440, 20022, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7441, 28077, 'Methyltestosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7442, 7196, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7443, 11072, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7444, 11073, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7445, 14146, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7446, 20022, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7447, 28077, 'Methyltestosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7448, 7196, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7449, 11072, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7450, 11073, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7451, 14146, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7452, 20022, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7453, 28077, 'Methyltestosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7454, 7196, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7455, 11072, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7456, 11073, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7457, 14146, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7458, 20022, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7459, 28077, 'Methyltestosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7460, 7196, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7461, 11072, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7462, 11073, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7463, 14146, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7464, 20022, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7465, 28077, 'Methyltestosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7466, 7196, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7467, 11072, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7468, 11073, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7469, 14146, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7470, 20022, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7471, 28077, 'Methyltestosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7472, 7196, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7473, 11072, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7474, 11073, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7475, 14146, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7476, 20022, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7477, 28077, 'Methyltestosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7478, 7196, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7479, 11072, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7480, 11073, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7481, 14146, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7482, 20022, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7483, 28077, 'Methyltestosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '"Product Information. Halotestin (fluoxymesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Androderm (testosterone topical)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7484, 516, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7485, 2797, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7486, 7824, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7487, 7825, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7488, 7826, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7489, 7827, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7490, 7828, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7491, 8097, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7492, 25000, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7493, 25001, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7494, 25002, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7495, 25257, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7496, 25259, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7497, 25261, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7498, 27683, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7499, 29582, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (7500, 29583, 'Metoclopramide', 'Depressive Disorder', 'Metoclopramide has been reported to cause mental depression in patients with and without a prior history of depression.  Symptoms have ranged from mild to severe and have included suicidal ideation and suicide.  Therapy with metoclopramide in patients with a history of mental depression, especially suicidal tendencies, should be administered cautiously, and only if benefits are anticipated to outweigh the potential risks.  Some patients who experience depression with metoclopramide have improved following temporary discontinuation of the drug and reinstitution at a lower dosage with gradual titration.', '3', 'Adams CD "Metoclopramide and depression." Ann Intern Med 103 (1985):  960|Bottner RK, Tullio CJ "Metoclopramide and depression." Ann Intern Med 103 (1985):  482|Feder R "Metoclopramide and depression." J Clin Psychiatry 48 (1987):  38|Weddington WW, Jr  Banner A "Organic affective syndrome associated with metoclopramide: case report." J Clin Psychiatry 47 (1986):  208-9|"Product Information. Reglan (metoclopramide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
